Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
ALVO is expected to report earnings to fall 109.66% to -3 cents per share on August 13
Q2'25
Est.
$-0.03
Q1'25
Beat
by $0.32
Q4'24
Missed
by $0.15
Q3'24
Beat
by $0.03
Q2'24
Missed
by $0.59
The last earnings report on May 07 showed earnings per share of 34 cents, beating the estimate of 2 cents. With 154.46K shares outstanding, the current market capitalization sits at 3.48B.